Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

WINT

Windtree Therapeutics (WINT)

Windtree Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:WINT
DateTimeSourceHeadlineSymbolCompany
12/16/20248:00AMGlobeNewswire Inc.Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials ConferenceNASDAQ:WINTWindtree Therapeutics Inc
12/09/20248:00AMGlobeNewswire Inc.Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial ArrhythmiaNASDAQ:WINTWindtree Therapeutics Inc
12/05/20247:12AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
12/04/20248:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
12/04/20248:00AMGlobeNewswire Inc.Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic TransactionNASDAQ:WINTWindtree Therapeutics Inc
11/27/20244:43PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
11/27/20244:05PMGlobeNewswire Inc.Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business UpdatesNASDAQ:WINTWindtree Therapeutics Inc
11/14/20248:53AMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:WINTWindtree Therapeutics Inc
11/14/20248:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
11/14/20248:00AMGlobeNewswire Inc.Windtree Announces Leadership Transition Plan With Industry VeteransNASDAQ:WINTWindtree Therapeutics Inc
11/04/20248:00AMGlobeNewswire Inc.Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong KongNASDAQ:WINTWindtree Therapeutics Inc
10/30/20248:00AMGlobeNewswire Inc.Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3NASDAQ:WINTWindtree Therapeutics Inc
10/23/20248:00AMGlobeNewswire Inc.Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the WorldNASDAQ:WINTWindtree Therapeutics Inc
10/21/20248:00AMGlobeNewswire Inc.Windtree To Present at the ThinkEquity Conference on October 30thNASDAQ:WINTWindtree Therapeutics Inc
10/17/20248:15AMGlobeNewswire Inc.Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for JapanNASDAQ:WINTWindtree Therapeutics Inc
10/09/20248:00AMGlobeNewswire Inc.Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial DesignNASDAQ:WINTWindtree Therapeutics Inc
10/09/20247:46AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:WINTWindtree Therapeutics Inc
09/30/20248:15AMGlobeNewswire Inc.Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic ShockNASDAQ:WINTWindtree Therapeutics Inc
09/26/20244:05PMGlobeNewswire Inc.Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ETNASDAQ:WINTWindtree Therapeutics Inc
09/25/20248:15AMGlobeNewswire Inc.Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic ShockNASDAQ:WINTWindtree Therapeutics Inc
09/25/20248:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
09/24/20245:21PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
09/04/20248:00AMGlobeNewswire Inc.Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic ShockNASDAQ:WINTWindtree Therapeutics Inc
09/04/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:WINTWindtree Therapeutics Inc
09/04/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:WINTWindtree Therapeutics Inc
09/03/20249:10AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:WINTWindtree Therapeutics Inc
09/03/20249:09AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:WINTWindtree Therapeutics Inc
09/03/20247:26AMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:WINTWindtree Therapeutics Inc
09/03/20247:22AMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:WINTWindtree Therapeutics Inc
08/23/20244:15PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:WINTWindtree Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:WINT

Your Recent History

Delayed Upgrade Clock